Abstract
The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic pro-gress of traditionally targeted gene mutations EGFR, ALK and ROS1, as well as new established or promising targets.
Mutations in the BRAF, NTRK, RET, cMET, HER2 and KRAS genes are dis-cussed in this regard. In EGFR mutations, it focuses mainly on possible combination therapy and treatment for mutations in exon 20.
In ALK translocation, it points to a new generation of tyrosine kinase inhibitors. In ROS1, the article mentions possible treatment in addition to the usual krizotinib, including the treatment after disease progression.
For other genes, the author lists newly approved molecules, or molecules in the promising phase of their development.